Information  X 
Enter a valid email address

Ilika plc (IKA)

  Print          Annual reports

Thursday 20 January, 2022

Ilika plc

Half-year Report

RNS Number : 0198Z
Ilika plc
20 January 2022
 

Ilika plc

('Ilika,' the 'Company,' or the 'Group')

 

Half-year Report

 

Ilika (AIM: IKA), a pioneer in solid-state battery technology, announces its unaudited half-year report for the six months ended 31 October 2021.

 

Operating Highlights

Ilika has continued to develop and commercialise its thin-film Stereax Ò   miniature solid-state batteries for powering medical devices and industrial wireless sensors (IIoT) in hostile environments, as well as progressing its development of large-format Goliath cells for electric vehicles (EV) and cordless appliances.

 

· Secured lease of a 1,600m2 property for Stereax manufacturing scale-up

· Completed the design, installation and commissioning of the 340 m2 Stereax clean room facility

· Completed installation of Stereax manufacturing line on time and on budget

· Commenced Stereax manufacturing process qualification

· Continued to engage with portfolio of Stereax customers from IIoT and medical device sector

· Completed Goliath development collaborations with Faraday Battery Challenge partners including Honda, JLR and McLaren

· Continued technical progress with the Goliath development programme, including increased cycle count, reduced operating temperature and increased energy density

· Commenced Goliath scale up manufacturing design collaboration with Comau, funded by the Advanced Propulsion Centre

· Appointed senior additions to management team with Brenadan McCarthy as Goliath Operations Director and Robin Bell as VP Product Development.  

 

Financial Summary

· In July 2021, raised c.£25m through a combination of an equity placing, a retail offer and an open offer

· Total revenue for the period £0.2m (H1 2021: £1.3m)

Ø Recognition of the initial allocation of Faraday Battery Challenge grant funding was completed at the start of the period, resulting in revenue recognition for the period of £0.2m

Ø The environment for grant funding has become tighter but we expect around £0.2m in H2

· Loss per share 2p (H1 2021: 1p)

· EBITDA loss £2.7m (H1 2021: £1.0m)

Ø The EBITDA loss was due to the reduction in revenue recognition and the increase in operational costs associated with the commissioning of the Stereax manufacturing facility and an intensification of the Goliath development programme

· Cash balance at period end £27.7m (H1 2021: £12.4m).

Ø Cash and cash equivalents at the period end were £27.7m following the placing, retail offer and open offer in July raising a net £23.7m

 

Post Period End

· Officially opened its Stereax Solid-State battery manufacturing facility in Chandlers Ford to manufacture micro batteries

 

Commenting on the results Graeme Purdy, CEO of Ilika, said:  "Our Stereax manufacturing facility has been implemented on time and on budget, despite significant supply chain disruption. I'd like to thank our employees, partners and shareholders for their support in making this happen. At the same time, our Goliath technical programme has made giant steps forwards particularly in operating temperature and cycle life, the equity placing completed in July 2021 will allow us to continue to progress towards manufacturing readiness."

 

Ilika plc

Graeme Purdy, Chief Executive

Steve Boydell, Finance Director

 

Liberum Capital Limited

Andrew Godber, Cameron Duncan,

William Hall, Nikhil Varghese

 

Joh. Berenberg, Gossler & Co. KG (Joint Broker)

Emily Morris, Detlir Elezi,

Alamgir Ahmed, Milo Bonser

 

 

Walbrook PR Ltd

Lianne Applegarth

Mob: +44 (0)7584 391 303

Nick Rome

Mob: +44 (0)7748 325 236

Tom Cooper

Mob: +44 (0)7971 221 972

 

Joint Chairman's and CEO's Statement

Review of Period

 

Principal Activities

Ilika has continued to pursue its strategy of developing and commercialising its cutting-edge solid-state batteries. The Company's mission is to rapidly develop leading-edge IP, manufacture and sell solid-state batteries for markets that cannot be addressed with conventional batteries due to their safety, charge rates, energy density and life limits. We will achieve this using ceramic-based lithium-ion technology that is inherently safe in manufacture and usage, which differentiates our products from existing batteries.

 

Throughout the year to date, including during the lockdown periods, the Company's facilities have remained open. Through the implementation of risk assessments, enhanced cleaning and hygiene procedures and social distancing, we have maintained a safe working environment.

 

 

Introduction to Stereax® solid-state battery technology

Ilika has been working with solid-state battery technology since 2008 and has developed a type of lithium-ion battery, which, instead of using liquid or polymer electrolyte, uses a ceramic ion conductor. Ilika's solid-state batteries have a number of benefits over traditional lithium-ion batteries, including the following:

· Non-flammable, which eliminates the need for containment packaging

· 6 x faster charging

· 2x increased energy density, making them half the volume and weight for a given electrical charge

· 10x longer storage without loss of charge

 

Ilika has developed a roadmap and family of battery products, ranging from miniature solid-state devices designed for powering wireless sensor applications and medical devices to large format cells for automotive power.

 

Miniature Stereax batteries

Ilika's miniature Stereax cells are differentiated from other solid-state technology through its choice of materials and its use of an efficient, low temperature evaporation process that is capable of higher manufacturing rates than other existing solid-state routes. This results in the following benefits relative to previous solid-state battery designs:

· Lower cost of manufacture through avoiding use of expensive sputtering targets

· Long cycle life through use of a silicon anode

· Less encapsulation required

· High temperature resilience

 

The unique benefits of Stereax batteries make them particularly useful for medical implants and industrial applications. Miniature Stereax batteries can enable medical devices in a way that is currently not possible with conventional lithium-ion batteries. Their compact, high energy density, high power characteristics make them useful for a range of medical implant applications covering blood pressure monitoring to neuro-stimulation. Industrial automation, or Industrial Internet of Things (IIoT) as it is sometimes referred to, requires low maintenance batteries with a long lifetime, sometimes in situations that require them to operate at elevated temperatures above those for which standard lithium-ion batteries are rated (typically 60 degC).

 

Stereax® Manufacturing Scale-up and Commercialisation

In 2020, Ilika had raised funds to support the transfer of Stereax to a manufacturing facility. Having assessed various manufacturing options, the Company concluded that the most efficient and cost-effective solution was to establish its own manufacturing operation. Long lead equipment items were ordered, the lease on a suitable property was secured and a contract was awarded for the design, installation and commissioning of a clean room facility. In September 2021, Ilika announced that it had completed the installation of the clean room and principal equipment. The total area of the leased property is 1,600 m2, in which a 340m2 clean room has been installed. In December 2021, Ilika announced the official opening of the facility by the Rt Hon Steve Brine MP and Rt Hon Lord Willetts, former Minister of State for Universities and Science. The official opening was followed up by a Capital Markets Day in which investors were invited to visit the facility. In line with previous guidance, process qualification continued through to the end of December 2021 and product qualification will start in Q1 2022.

 

The Company has continued to engage with its portfolio of customers from the IIoT and medical device sectors. The tolerance of Stereax cells of high temperatures makes them attractive for powering industrial sensors, while the benefits of Stereax batteries for medical devices, including miniaturised footprint, biocompatibility, zero risk of leakage and a long lifespan, underpin their design for applications including neurostimulation, orthopaedics, ophthalmic sensors and monitoring of heart rhythm and blood pressure. Commercial sales are expected to start in FY 2023 following product qualification. Product sales will be ramped up to match demand from a portfolio of customer new product development (NPD) programmes, with an initial focus on miniature medical devices.

 

Large Format Goliath batteries

In July 2021, the Company raised £25m through a combination of an equity placing, a retail offer and an open offer. Ilika outlined that £10m will be used to accelerate the development of Goliath technology to match and exceed lithium-ion equivalence; £5m will be used to fund a tenfold increase in capacity of the Goliath pre-pilot line from 1kWh to 10kWh per week and the remainder will used for working capital purposes and to support Goliath development until mid-2023. Beyond that, once cell manufacturing readiness is achieved in 2024, Ilika will transfer production to a mega-scale facility such as the UK-BIC, with which it has a framework agreement, before moving to Giga-scale through a JV or licensing.

 

The Company's initial development collaborations with its Faraday Battery Challenge partners including Honda, JLR and McLaren, have been completed. During the course of those collaborations, Ilika successfully achieved sustained technical progress, including increased cycle count, reduced operating temperature and increased energy density.

 

Work continues with Comau in a programme funded by the APC (Advanced Propulsion Centre) to design the Goliath mega-scale facility. Discussions are also progressing with other supply chain partners to support materials supply and cell manufacturing scale-up implementation.

 

Outlook

For the remainder of the current financial year, Ilika will continue to qualify the process established at its Stereax manufacturing facility and rapidly follow up with product qualification. Commercial Stereax sales are expected to commence in the next financial year. The technical maturity of Goliath is expected to continue to rise as prototype cell performance continuously improves.

 

Graeme Purdy, CEO

Keith Jackson, Chairman

Ilika plc
 

Consolidated statement of comprehensive income for the six months ended 31 October 2021

 

 

 

Unaudited

 Six months ended

31 Oct 2021

Unaudited

 Six months ended

31 Oct 2020

Audited

Year

ended

30 Apr 2021

 

Notes

£

£

£

 

 

 

 

 

Turnover

 

195,418

1,250,249

2,255,688

Revenue

 

15,932

83,253

230,453

UK grants

 

179,486

1,166,996

2,025,235

 

 

 

 

 

Cost of sales

 

(125,257)

(705,045)

(1,271,612)

 

 

 

 

 

Gross profit

 

70,161 

545,204 

984,076 

Administrative expenses

 

 

 

 

Administrative expenses

 

(3,301,949)

(2,136,592)

(4,405,622)

Share-based payment charge

 

(248,504)

(163,787)

(419,591)

 

 

(3,550,453)

(2,300,379)

(4,825,213)

 

 

 

 

 

Operating loss

 

(3,480,292)

(1,755,175)

(3,841,137)

 

 

 

 

 

Financial income

 

2,867 

9,032 

14,806 

Financial expense

 

(14,675)

(4,000)

(9,694)

 

 

 

 

 

Loss before tax

 

(3,492,100)

(1,750,143)

(3,836,025)

Taxation

 

225,000 

128,962 

308,962 

 

 

 

 

 

Loss for period/total comprehensive income attributable to owners of parent

 

 

(3,267,100)

 

(1,621,181)

 

(3,527,063)

 

 

 

 

 

Loss per share

 

 

 

 

Basic and diluted

2

(0.02)

(0.01)

(0.03)

 

The results from the periods shown above are derived entirely from continuing operations.

 

Consolidated balance sheet as at 31 October 2021

 

 

 

Unaudited

Six months ended

31 Oct 2021

Unaudited

Six months ended

31 Oct 2020

Audited

Year

ended

30 Apr 2021

 

Notes

£

£

£

ASSETS

 

 

Non-current assets

 

 

Intangible assets

1,737,318

467,166

Property, plant and equipment

4,843,932

2,043,105

Right-of-use assets

785,765

208,034

 

 

 

Total non-current assets

7,367,015

2,718,305

 

 

 

Current assets

 

 

Trade and other receivables

2,053,304

1,809,990

Current tax receivable

555,000

428,962

Other financial assets - bank deposits

770,903

765,696

Cash and cash equivalents

26,933,312

11,661,566

 

 

 

Total current assets

30,312,519

14,666,214

 

 

 

Total assets

37,679,534

17,384,519

 

 

 

Issued capital and reserves attributable to owners of parent

 

 

 

Issued share capital

1,574,679 

1,391,857 

Share premium

64,698,829 

40,895,709 

Capital restructuring reserve

6,486,077 

6,486,077 

Retained earnings

(37,706,618)

(33,037,944)

 

 

 

Total equity

35,052,967

15,735,699

 

 

 

LIABILITIES

 

 

Current liabilities

 

 

Trade and other payables

1,759,570

1,316,616

Lease liabilities

195,524

68,875

 

 

 

Total current liabilities

1,955,094

1,385,491

 

 

 

Non-current liabilities

 

 

Lease liabilities

531,108

122,964

Provisions

 

140,365

140,365

 

 

 

Total non-current liabilities

671,473

263,329

 

 

 

Total liabilities

2,626,567

1,648,820

 

 

 

Total equity and liabilities

37,679,534

17,384,519

 

Consolidated cash flow statement for the six months ended 31 October 2021

 

 

Unaudited

Six months ended

31 Oct 2021

Unaudited

Six months ended

31 Oct 2020

Audited

Year

ended

30 Apr 2021

 

£

£

£

Cash flows from operating activities

 

 

 

Loss before taxation

(3,492,100)

(1,750,143)

Adjustments for:

 

 

 

Amortisation

47,117 

6,697 

14,243 

Depreciation

486,299 

551,605 

Equity settled share-based payments

248,504 

163,787 

Loss on disposal of plant, property and equipment

-

1,557 

Net financial expense/ (income)

11,808

(5,032)

Operating cash flow before changes in working capital, interest and taxes

(2,698,372)

(1,031,529)

Decrease/(increase) in trade and other

receivables

 

120,293

 

(339,326)

Increase /(decrease) in trade and other payables

386,360

406,315 

Decrease in provisions

-

(29,304)

Cash utilised by operations

(2,191,719)

(993,844)

Tax received

Net cash flow from operating activities

(2,191,719)

(993,844)

 

 

 

Cash flows from investing activities

 

 

Interest received

2,866 

9,033 

Purchase of intangible assets

(721,375)

(407,753)

Purchase of property, plant and equipment

(2,920,392)

(893,649)

Increase in other financial assets

(1,822)

(3,496)

Net cash used in investing activities

(3,640,723)

(1,295,865)

 

 

 

Cash flows from financing activities

 

 

Proceeds from issuance of ordinary share capital

24,769,724

Cost of share issue

(885,414)

Capital element of finance leases repaid

(115,763)

(38,263)

Net cash from financing activities

23,768,547

(38,263)

 

 

 

Net (decrease)/ increase in cash and cash equivalents

17,936,105

(2,327,972)

 

 

 

Cash and cash equivalents at the start of the period

8,997,208 

13,989,538 

 

 

 

Cash and cash equivalents at the end of the period

26,933,313

11,661,566 

 

 

Consolidated statement of changes in equity (unaudited)

 

 

 

Share capital

Share premium account

Capital

restructuring reserve

 

Retained earnings

 

 

Total

 

£

£

£

£

£

As at 30th April 2020

1,391,857

40,895,709

6,486,077

(31,580,550)

17,193,093 

Share-based payment

-

-

-

163,787 

Loss and total

comprehensive income

 

-

 

-

 

-

 

(1,621,181)

As at 31 October 2020

1,391,857

40,895,709

6,486,077

(33,037,944)

15,735,699 

Share-based payment

-

-

-

255,804 

Issue of shares

4,408

97,224

-

101,632 

Loss and total

comprehensive income

 

-

 

-

 

-

(1,905,882)

As at 30th April 2021

1,396,265

40,992,933

6,486,077

(34,688,022)

14,187,253 

Share-based payment

-

-

-

248,504

Issue of shares

178,414

24,591,311

-

24,769,724

Cost of share issue

-

(885,414)

-

(885,414)

Loss and total

comprehensive income

 

-

 

-

 

-

 

(3,267,100)

As at 31 October 2021

1,574,679

64,678,040

6,486,077

(37,706,618)

35,052,967

 

Share capital

The share capital represents the nominal value of the equity shares in issue.

 

Share premium account

When shares are issued, any premium paid above the nominal value is credited to the share premium reserve.

 

Retained earnings

The retained earnings reserve records the accumulated profits and losses of the Group since inception of the business.

 

Capital restructuring reserve

The capital restructuring reserve arises on the accounting for the share for share exchange.  It represents the difference between the value of the issued equity instruments of Ilika Technologies Limited immediately before the share for share exchange and the equity instruments of Ilika plc along with the shares issued to effect the share for share exchange.

 

Notes to the consolidated financial statements

 

1.  Accounting policies

 

Basis of preparation

 

The interim financial statements, which are unaudited, have been prepared on the basis of accounting policies consistent with International Financial Reporting Standards ("IFRSs") adopted by the European Union. The accounting policies are the same as applied in the Group's latest financial statements.

 

The interim financial statements do not include all of the information required for full annual financial statements and do not comply with all the disclosures in IAS 34 'Interim Financial Reporting'. Accordingly, whilst the interim financial statements have been prepared in accordance with IFRS they cannot be construed as being in full compliance with IFRS.

 

The financial information for the year ended 30 April 2021 does not constitute the full statutory accounts for that period. The Annual Report and Accounts for 30 April 2021 have been filed with the Registrar of Companies. The Independent Auditors' Report on the Annual Report and Accounts for 2021 was unqualified and did not include references to any matters which the auditors drew attention by way of emphasis without qualifying their report and did not contain statements under Section 498(2) or 498(3) of the Companies Act 2006.

 

Going concern

 

The financial statements are prepared on a going concern basis which the directors believe continues to be appropriate. The Group meets its day to day working capital requirements through existing cash resources which, at 31 October 2021, amounted to £27.7m. The directors have prepared projected cash flow information for the period ending twelve months from the date of their approval of these financial statements. On the basis of this cash flow information the directors believe that the Group will be able to continue to trade for the foreseeable future.

 

 

2.  Loss per share

 

Loss per ordinary share have been calculated using the weighted average number of shares in issue during the relevant financial periods. The weighted average number of equity shares in issue and the earnings, being loss after tax, are as follows:

 

 

Unaudited

Six months ended

31 Oct 2021

 

Unaudited

Six months ended

31 Oct 2020

 

Audited

Year

ended

30 Apr 2021

 

Number

Number

Number

 

Weighted average number of equity shares

 

 

£

£

£

 

Loss, being loss after tax

 

 

The loss attributable to ordinary shareholders and weighted average number of ordinary shares for the purpose of calculating the diluted earnings per ordinary share are identical to those used for basic earnings per share. This is because the exercise of share options and warrants would have the effect of reducing the loss per ordinary share and is therefore not dilutive under the terms of IAS 33.

 

 

 

 

 

- Ends -

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IR KKLFFLFLZBBX

a d v e r t i s e m e n t